Correspondence 0001213900-23-047675 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: June 9, 2023 · CIK: 0001601936 · Accession: 0001213900-23-047675
AI Filing Summary & Sentiment
File numbers found in text: 333-272336
Letter
Re: Altamira Therapeutics Ltd. (the “Company”)
June 9, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-1 (File No. 333-272336)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 p.m. Eastern Time on Friday, June 9, 2023, or as soon thereafter as is practicable.
Please call Alexander Dinur of Lowenstein Sandler LLP at 973-422-6732 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
Altamira Therapeutics Ltd.
Show Raw Text
CORRESP
1
filename1.htm
June 9, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Altamira Therapeutics Ltd. (the “Company”)
Registration Statement on Form F-1 (File No. 333-272336)
Ladies and Gentlemen:
In accordance with Rule 461 under
the Securities Act of 1933, as amended, the Company hereby requests that the effective date for the Registration Statement referred to
above be accelerated so that it will be declared effective at 4:30 p.m. Eastern Time on Friday, June 9, 2023, or as soon thereafter as
is practicable.
Please call Alexander Dinur of
Lowenstein Sandler LLP at 973-422-6732 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
Altamira Therapeutics Ltd.
By:
/s/ Thomas Meyer
Name:
Thomas Meyer
Title:
Chief Executive Officer